Cargando…

Why isn’t the angiotensin type 1 receptor a target in cancer?

Detalles Bibliográficos
Autor principal: Vinson, Gavin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386630/
https://www.ncbi.nlm.nih.gov/pubmed/28423631
http://dx.doi.org/10.18632/oncotarget.15682
_version_ 1782520805059461120
author Vinson, Gavin P.
author_facet Vinson, Gavin P.
author_sort Vinson, Gavin P.
collection PubMed
description
format Online
Article
Text
id pubmed-5386630
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53866302017-04-26 Why isn’t the angiotensin type 1 receptor a target in cancer? Vinson, Gavin P. Oncotarget News Impact Journals LLC 2017-02-24 /pmc/articles/PMC5386630/ /pubmed/28423631 http://dx.doi.org/10.18632/oncotarget.15682 Text en Copyright: © 2017 Vinson http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle News
Vinson, Gavin P.
Why isn’t the angiotensin type 1 receptor a target in cancer?
title Why isn’t the angiotensin type 1 receptor a target in cancer?
title_full Why isn’t the angiotensin type 1 receptor a target in cancer?
title_fullStr Why isn’t the angiotensin type 1 receptor a target in cancer?
title_full_unstemmed Why isn’t the angiotensin type 1 receptor a target in cancer?
title_short Why isn’t the angiotensin type 1 receptor a target in cancer?
title_sort why isn’t the angiotensin type 1 receptor a target in cancer?
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386630/
https://www.ncbi.nlm.nih.gov/pubmed/28423631
http://dx.doi.org/10.18632/oncotarget.15682
work_keys_str_mv AT vinsongavinp whyisnttheangiotensintype1receptoratargetincancer